Clearmind Medicine applies for a patent for combination therapy using MDMA and PEA, partnering with SciSparc Ltd to enhance safety and efficacy.

Clearmind Medicine has announced an international patent application for a combination therapy using MDMA and N-Acylethanolamines, including Palmitoylethanolamide (PEA). This collaboration with SciSparc Ltd. aims to enhance safety and therapeutic efficacy, addressing FDA concerns over MDMA's safety. The companies have filed multiple patents, seeking to innovate treatments for mental health disorders and addictions while reducing MDMA dosages.

September 06, 2024
3 Articles